GBA1 and Parkinson disease: As ambroxol is also a chaperone for GBA1, thereby reducing a-synuclein aggregates, it is being explored clinically in Parkinson’s disease (NCT02941822, NCT05778617, NCT05830396, NCT06193421, NCT02914366, NCT05287503, NCT04388969), Lewy Body dementia (NCT04588285), and in neuronopathic Gaucher’s disease [172].